期刊
MOLECULAR PHARMACEUTICS
卷 16, 期 5, 页码 2060-2068出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.9b00036
关键词
prostate cancer; MNP; magnetic resonance imaging; optical imaging; magnetic hyperthermia therapy
资金
- National Institutes of Health [R01CA134675, U01CA183031, P50CA058236, P41EB024495, K25CA148901]
Magnetic nanoparticle (MNP)-induced hyperthermia is currently being evaluated for localized prostate cancer. We evaluated the feasibility of tumor-selective delivery of prostate-specific membrane antigen (PSMA)-targeted MNPs in a murine model with high-resolution magnetic resonance imaging (MRI) after intravenous administration of MNPs at a concentration necessary for hyperthermia. A PSMA-targeted MNP was synthesized and evaluated using T-2-weighted MRI, after intravenous administration of 50 mg/kg of the MNP. Significant contrast enhancement (P < 0.0002, n = 5) was observed in PSMA(+) tumors compared to PSMA(-) tumors 24 h and 48 h after contrast agent administration. Mice were also imaged with near-infrared fluorescence imaging, to validate the MRI results. Two-photon microscopy revealed higher vascular density at the tumor periphery, which resulted in higher peripheral accumulation of PSMA-targeted MNPs. These results suggest that the delivery of PSMA-targeted MNPs to PSMA(+) tumors is both actively targeted and passively mediated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据